ECSP045054A - Composicion farmaceutica para utilizarse para el tratamiento de malignidades, que comprende una combinacion de bisfosfonatos, un inhibidor de cox-2 y un taxol - Google Patents
Composicion farmaceutica para utilizarse para el tratamiento de malignidades, que comprende una combinacion de bisfosfonatos, un inhibidor de cox-2 y un taxolInfo
- Publication number
- ECSP045054A ECSP045054A EC2004005054A ECSP045054A ECSP045054A EC SP045054 A ECSP045054 A EC SP045054A EC 2004005054 A EC2004005054 A EC 2004005054A EC SP045054 A ECSP045054 A EC SP045054A EC SP045054 A ECSP045054 A EC SP045054A
- Authority
- EC
- Ecuador
- Prior art keywords
- taxol
- cox
- inhibitor
- treatment
- pharmaceutical composition
- Prior art date
Links
- 229940122361 Bisphosphonate Drugs 0.000 title abstract 3
- 229930012538 Paclitaxel Natural products 0.000 title abstract 3
- 150000004663 bisphosphonates Chemical class 0.000 title abstract 3
- 229940111134 coxibs Drugs 0.000 title abstract 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title abstract 3
- 229960001592 paclitaxel Drugs 0.000 title abstract 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000003211 malignant effect Effects 0.000 abstract 2
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 206010027452 Metastases to bone Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describe una composición farmacéutica para el tratamiento de malignidades, en particular una enfermedad maligna, la cual está asociada con el desarrollo de metástasis ósea o reabsorción excesiva de huesos, que comprende en combinación un bisfosfonato, un inhibidor de COX-2 y/o un taxol o derivado del mismo, para uso simultáneo, secuencial o separado. También se proporciona un método para tratar a un paciente que padece de una enfermedad maligna, que comprende administrar al paciente una cantidad efectiva de un bisfosfonato, una cantidad efectiva de un inhibidor de COX-2 y/o una cantidad efectiva de un taxol o derivado del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34592101P | 2001-10-19 | 2001-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045054A true ECSP045054A (es) | 2004-05-28 |
Family
ID=23357099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005054A ECSP045054A (es) | 2001-10-19 | 2004-04-08 | Composicion farmaceutica para utilizarse para el tratamiento de malignidades, que comprende una combinacion de bisfosfonatos, un inhibidor de cox-2 y un taxol |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7345088B2 (es) |
| EP (1) | EP1443942B1 (es) |
| JP (1) | JP2005506371A (es) |
| KR (1) | KR20040066103A (es) |
| CN (1) | CN100372539C (es) |
| AT (1) | ATE382347T1 (es) |
| AU (1) | AU2002363089B2 (es) |
| BR (1) | BR0213410A (es) |
| CA (1) | CA2461085A1 (es) |
| CO (1) | CO5570672A2 (es) |
| DE (1) | DE60224429T2 (es) |
| DK (1) | DK1443942T3 (es) |
| EC (1) | ECSP045054A (es) |
| ES (1) | ES2301710T3 (es) |
| HU (1) | HUP0402061A3 (es) |
| IL (2) | IL161090A0 (es) |
| MX (1) | MXPA04003671A (es) |
| NO (1) | NO20042056L (es) |
| NZ (1) | NZ532282A (es) |
| PL (1) | PL367707A1 (es) |
| PT (1) | PT1443942E (es) |
| RU (1) | RU2317819C2 (es) |
| SI (1) | SI1443942T1 (es) |
| WO (1) | WO2003035081A1 (es) |
| ZA (1) | ZA200402089B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0204756D0 (en) * | 2002-02-28 | 2002-04-17 | Novartis Ag | Organic compounds |
| GB0328040D0 (en) * | 2003-12-03 | 2004-01-07 | Coleman Robert E | Pharmaceutical uses of bisphosphonates |
| FR2939314A1 (fr) * | 2008-12-04 | 2010-06-11 | Univ Victor Segalen Bordeaux 2 | Nouvelles compositions et methodes pour la potentialisation des signaux d'apoptose dans les cellules tumorales |
| WO2011014766A2 (en) | 2009-07-31 | 2011-02-03 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US20160016982A1 (en) | 2009-07-31 | 2016-01-21 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9169279B2 (en) | 2009-07-31 | 2015-10-27 | Thar Pharmaceuticals, Inc. | Crystallization method and bioavailability |
| US9340565B2 (en) | 2010-11-24 | 2016-05-17 | Thar Pharmaceuticals, Inc. | Crystalline forms |
| US10195218B2 (en) | 2016-05-31 | 2019-02-05 | Grunenthal Gmbh | Crystallization method and bioavailability |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187130A (zh) * | 1995-06-06 | 1998-07-08 | 麦克公司 | 用二磷酸盐预防与免疫抑制疗法有关的骨损失 |
| CZ20012321A3 (cs) | 1998-12-23 | 2002-10-16 | G. D. Searle & Co. | Léčivo s obsahem inhibitoru cyklooxygenázy-2 a inhibitoru matricové metaloproteinázy pro kombinační terapii při léčení neoplasie |
| WO2001054688A1 (en) * | 2000-01-28 | 2001-08-02 | Merck & Co., Inc. | Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug |
-
2002
- 2002-10-18 KR KR10-2004-7005630A patent/KR20040066103A/ko not_active Ceased
- 2002-10-18 WO PCT/EP2002/011696 patent/WO2003035081A1/en not_active Ceased
- 2002-10-18 EP EP02801899A patent/EP1443942B1/en not_active Expired - Lifetime
- 2002-10-18 PT PT02801899T patent/PT1443942E/pt unknown
- 2002-10-18 MX MXPA04003671A patent/MXPA04003671A/es active IP Right Grant
- 2002-10-18 BR BR0213410-1A patent/BR0213410A/pt not_active IP Right Cessation
- 2002-10-18 CA CA002461085A patent/CA2461085A1/en not_active Abandoned
- 2002-10-18 DK DK02801899T patent/DK1443942T3/da active
- 2002-10-18 JP JP2003537648A patent/JP2005506371A/ja active Pending
- 2002-10-18 IL IL16109002A patent/IL161090A0/xx unknown
- 2002-10-18 DE DE60224429T patent/DE60224429T2/de not_active Expired - Fee Related
- 2002-10-18 US US10/493,042 patent/US7345088B2/en not_active Expired - Fee Related
- 2002-10-18 AU AU2002363089A patent/AU2002363089B2/en not_active Ceased
- 2002-10-18 CN CNB028207823A patent/CN100372539C/zh not_active Expired - Fee Related
- 2002-10-18 SI SI200230676T patent/SI1443942T1/sl unknown
- 2002-10-18 ES ES02801899T patent/ES2301710T3/es not_active Expired - Lifetime
- 2002-10-18 HU HU0402061A patent/HUP0402061A3/hu unknown
- 2002-10-18 RU RU2004115337/15A patent/RU2317819C2/ru not_active IP Right Cessation
- 2002-10-18 NZ NZ532282A patent/NZ532282A/en unknown
- 2002-10-18 AT AT02801899T patent/ATE382347T1/de not_active IP Right Cessation
- 2002-10-18 PL PL02367707A patent/PL367707A1/xx not_active Application Discontinuation
-
2004
- 2004-03-16 ZA ZA200402089A patent/ZA200402089B/en unknown
- 2004-03-25 IL IL161090A patent/IL161090A/en not_active IP Right Cessation
- 2004-04-08 EC EC2004005054A patent/ECSP045054A/es unknown
- 2004-04-15 CO CO04034537A patent/CO5570672A2/es not_active Application Discontinuation
- 2004-05-18 NO NO20042056A patent/NO20042056L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003035081A1 (en) | 2003-05-01 |
| IL161090A0 (en) | 2004-08-31 |
| RU2317819C2 (ru) | 2008-02-27 |
| ES2301710T3 (es) | 2008-07-01 |
| US20050014726A1 (en) | 2005-01-20 |
| US7345088B2 (en) | 2008-03-18 |
| PT1443942E (pt) | 2008-04-07 |
| HK1080733A1 (en) | 2006-05-04 |
| CA2461085A1 (en) | 2003-05-01 |
| IL161090A (en) | 2010-04-15 |
| NO20042056L (no) | 2004-05-18 |
| CO5570672A2 (es) | 2005-10-31 |
| ATE382347T1 (de) | 2008-01-15 |
| JP2005506371A (ja) | 2005-03-03 |
| DE60224429D1 (de) | 2008-02-14 |
| AU2002363089B2 (en) | 2006-02-16 |
| EP1443942B1 (en) | 2008-01-02 |
| NZ532282A (en) | 2006-02-24 |
| CN100372539C (zh) | 2008-03-05 |
| RU2004115337A (ru) | 2005-04-20 |
| CN1703226A (zh) | 2005-11-30 |
| HUP0402061A3 (en) | 2007-05-29 |
| MXPA04003671A (es) | 2005-06-20 |
| DK1443942T3 (da) | 2008-05-19 |
| ZA200402089B (en) | 2005-06-22 |
| KR20040066103A (ko) | 2004-07-23 |
| PL367707A1 (en) | 2005-03-07 |
| HUP0402061A2 (hu) | 2005-02-28 |
| DE60224429T2 (de) | 2008-12-18 |
| EP1443942A1 (en) | 2004-08-11 |
| SI1443942T1 (sl) | 2008-08-31 |
| BR0213410A (pt) | 2004-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0207961B8 (pt) | uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos. | |
| AR109605A2 (es) | Método para tratar enfermedades vasculares periféricas, composición y utilización | |
| ATE312635T1 (de) | Ventilanordnung | |
| AR033175A1 (es) | Usos farmaceuticos de bisfosfonatos | |
| AR045179A1 (es) | Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer | |
| NO20034549L (no) | Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV | |
| AR029763A1 (es) | Uso de una combinacion de una nsaid y un inhibidor de quinasa egfr para la manufactura de un medicamento para el tratamiento o inhibicion de polipos colonicos y cancer colorectal, composicion farmaceutica y medicamento | |
| CR8012A (es) | Clavo endomedular destinado al tratamiento de fracturas de femur proximal | |
| DK1272188T3 (da) | Anvendelse af EGFR-tyrosinkinaseinhibitorer til behandling af brystcancer | |
| BRPI0415896A (pt) | combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia | |
| CY1114422T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει αρσενικωδες για τη θεραπευτικη αντιμετωπιση κακοηθειας | |
| DE60105025D1 (de) | Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie | |
| MX2007000117A (es) | Una composicion de combinacion. | |
| ECSP045054A (es) | Composicion farmaceutica para utilizarse para el tratamiento de malignidades, que comprende una combinacion de bisfosfonatos, un inhibidor de cox-2 y un taxol | |
| TW200509863A (en) | Irradiation device for medical use | |
| BR0313081A (pt) | Combinação de um inibidor de aromatase com um bisfosfanato | |
| DE60115054D1 (de) | Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs | |
| BR0114856A (pt) | Combinação compreendendo camptotecina e um derivado de estilbeno para o tratamento de câncer | |
| FR2839450B1 (fr) | Preparation medicamenteuse notamment pour le traitement des hernies discales | |
| BR0315374A (pt) | Compostos orgânicos | |
| AR027677A1 (es) | Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer | |
| BR0315376A (pt) | Combinações de benzotiadiazóis e inibidores de cox-2 para o tratamento de dor | |
| AR026791A1 (es) | Metdo para prevenir o aliviar la diarrea causada por el agente quimioterapeutico irinotecano, administrando carbon al paciente. | |
| CL2004000758A1 (es) | Procedimiento de preparacion de compuestos derivados de 3-ciano-7-alcoxi-6-nitro-4-hidroxi-quinolona a partir de un antralinato. | |
| ATE411014T1 (de) | Bakuchiol enthaltende pharmazeutische zusammensetzung zur behandlung von weiblichem brustkrebs |